Antiviral treatments are becoming increasingly available for human viral diseases (HIV, HBV, HCV, influenza). As most of these viruses exist within patients as genetic variants, some of them might have mutations that confer resistance to the activity of the drugs. The use of viral genetic sequences to predict failure to antiviral treatment has made publicly available thousands of sequences. This is an invaluable source for many studies.
Some publications that we have been engaged with antiviral drug resistance
-Magiorkinis E, Paraskevis D, Magiorkinis G, Chryssou S, Chini M, Lazanas M,Paparizos V, Saroglou G, Antoniadou A, Giamarellou E, Karafoulidou A, Hatzakis A. Mutations associated with genotypic resistance to antiretroviral therapy in treatment naïve HIV-1 infected patients in Greece. Virus Research 85:109-15
-Ntziora F, Paraskevis D, Haida C, Magiorkinis E, Manesis E, Papatheodoridis G, Manolakopoulos S, Beloukas A, Chryssoy S, Magiorkinis G, Sypsa V, Hatzakis A. Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology. J Clin. Microbiol. 47:2544-50
-Magiorkinis E, Paraskevis D, Detsika MG, Lu L, Magiorkinis G, Lazanas M, Imbrechts S, Van Laethem K, Vandamme AM, Pilot-Matias T, Molla A, Camacho RJ, Hatzakis A. Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility. AIDS Res Hum Retroviruses. 27:1223-9